PPARA and metabolic dysfunction-associated steatotic liver disease: Inhibition of this miR in a mouse model had a therapeutic effect in NAFLD, which was associated with miR-34a-mediated repression of PPARα and subsequent suppression of fatty acid metabolism in the liver [42].